Lexaria Bioscience Corp.
Lexaria Bioscience Corp.
09/01/2026 | Press release | Distributed by Public on 09/01/2026 07:16
Material Event (Form 8-K)
Item 8.01 Other Events
Receipt of Australian R & D Tax Incentive Credit
On August 28, 2026, Lexaria (AU) Pty Ltd, the wholly-owned subsidiary of Lexaria Bioscience Corp. which holds the exclusive rights to use DehydraTECH technology with pharmaceutical GLP-1/GIP and CBD drug products in the territory of Australia, received a tax credit in the amount of AUD$3,666,611.98 (USD$2.6M), from the Australian Tax Office (the "Credit") in connection with the research and development costs associated with its Australian clinical study GLP-1-H24-4.
The Credit has been deposited into the Australian bank account of Lexaria (AU) Pty Ltd for the intended purpose of pursuing additional research and development opportunities in Australia.
| 2 |
Lexaria Bioscience Corp. published this content on September 01, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on September 01, 2026 at 13:17 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]